AbbVie’s Contract With Express Scripts Puts Gilead On Defense…And Industry On Notice
Executive Summary
Express Scripts decision to provide AbbVie’s new Viekira Pak as the exclusive treatment option for genotype 1 hepatitis C patients under its national preferred formulary leaves Gilead’s Sovaldi and Harvoni out in the cold and spotlights growing pricing pressure as payers are willing to deny coverage for market-leading drugs.
You may also be interested in...
Sanofi Steps Up To Lend A Hand Producing Pfizer/BioNTech's COVID-19 Vaccine In Europe
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.
J&J Forecasts Strong Pharma Growth In 2021, But No COVID-19 Vaccine Update
Data from a high-profile Phase III COVID-19 vaccine trial will be released the first week of February, management said.
Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: